Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects - Two prospective, multicentre, open-label, parallel-group volunteer studies
被引:40
作者:
Abel, Samantha
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, EnglandPfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
Abel, Samantha
[1
]
Allan, Richard
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Inc, New York, NY USAPfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
Allan, Richard
[2
]
Gandelman, Kuan
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Inc, New York, NY USAPfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
Gandelman, Kuan
[2
]
Tomaszewskil, Konrad
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, EnglandPfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
Tomaszewskil, Konrad
[1
]
Webb, David J.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Edinburgh, Clin Pharmacol Unit, Queens Med Res Inst, Ctr Cardiovasc Sci, Edinburgh, Midlothian, ScotlandPfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
Webb, David J.
[3
]
Wood, Nolan D.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, EnglandPfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
Wood, Nolan D.
[1
]
机构:
[1] Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
[2] Pfizer Inc, New York, NY USA
[3] Univ Edinburgh, Clin Pharmacol Unit, Queens Med Res Inst, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
Background and objectives: Since little is known regarding the pharmacokinetics of voriconazole in renally impaired patients, two prospective, open-label, parallel-group volunteer studies were conducted to estimate the effect of renal impairment on the pharmacokinetics of oral voriconazole and intravenous voriconazole solubilized with sulphobutylether-beta-cyclodextrin (SBECD), respectively. Methods: In study A, male subjects with no (n = 6), mild (n = 6), moderate (n = 6) or severe (n = 6) renal impairment received one 200 mg dose of oral voriconazole. Voriconazole plasma levels were periodically assessed until 48 hours post-dose. In study 13, male subjects with no (n = 6) or moderate (n = 7) renal impairment received multiple doses of intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily [day 1] then 3 mg/kg twice daily [days 2-6] followed by a final dose of 3 mg/kg on the morning of day 7) at an infusion rate of 3 mg/kg/h. Voriconazole plasma levels were periodically assessed until 36 hours following the final dose. Pharmacokinetics were determined by non-compartmental methods. Results: The pharmacokinetics of voriconazole were unaffected in subjects with any degree of renal impairment in both studies. In study B, clearance of SBECD was proportional to creatinine clearance (r(2) = 0.857). Although two subjects had >30% increase in serum creatinine from baseline, these changes did not correlate with SBECD trough levels (r(2) = 0.053). The majority of subjects with moderate renal insufficiency were able to tolerate 7 days of intravenous voriconazole solubilized with SBECD. Conclusion: These data suggest that renal impairment does not affect the pharmacokinetics of voriconazole. Furthermore, in subjects with moderate renal impairment, there is a strong linear correlation between SBECD clearance and creatinine clearance, and elevated SBECD levels do not necessarily correlate with increased serum creatinine levels (an indicator of worsening renal function).
机构:
Wayne State Univ, Sch Med, Detroit Med Ctr, Dept Med,Div Infect Dis, Detroit, MI 48201 USAWayne State Univ, Sch Med, Detroit Med Ctr, Dept Med,Div Infect Dis, Detroit, MI 48201 USA
Chandrasekar, PH
;
Manavathu, E
论文数: 0引用数: 0
h-index: 0
机构:
Wayne State Univ, Sch Med, Detroit Med Ctr, Dept Med,Div Infect Dis, Detroit, MI 48201 USAWayne State Univ, Sch Med, Detroit Med Ctr, Dept Med,Div Infect Dis, Detroit, MI 48201 USA
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
Cuenca-Estrella, M
;
Rodríguez-Tudela, JL
论文数: 0引用数: 0
h-index: 0
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
Rodríguez-Tudela, JL
;
Mellado, E
论文数: 0引用数: 0
h-index: 0
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
Mellado, E
;
Martínez-Suárez, JV
论文数: 0引用数: 0
h-index: 0
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
Martínez-Suárez, JV
;
Monzón, A
论文数: 0引用数: 0
h-index: 0
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
机构:
Virginia Commonwealth Univ, Med Coll Virginia, Div Infect Dis, Richmond, VA 23219 USAVirginia Commonwealth Univ, Med Coll Virginia, Div Infect Dis, Richmond, VA 23219 USA
机构:
Wayne State Univ, Sch Med, Detroit Med Ctr, Dept Med,Div Infect Dis, Detroit, MI 48201 USAWayne State Univ, Sch Med, Detroit Med Ctr, Dept Med,Div Infect Dis, Detroit, MI 48201 USA
Chandrasekar, PH
;
Manavathu, E
论文数: 0引用数: 0
h-index: 0
机构:
Wayne State Univ, Sch Med, Detroit Med Ctr, Dept Med,Div Infect Dis, Detroit, MI 48201 USAWayne State Univ, Sch Med, Detroit Med Ctr, Dept Med,Div Infect Dis, Detroit, MI 48201 USA
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
Cuenca-Estrella, M
;
Rodríguez-Tudela, JL
论文数: 0引用数: 0
h-index: 0
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
Rodríguez-Tudela, JL
;
Mellado, E
论文数: 0引用数: 0
h-index: 0
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
Mellado, E
;
Martínez-Suárez, JV
论文数: 0引用数: 0
h-index: 0
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
Martínez-Suárez, JV
;
Monzón, A
论文数: 0引用数: 0
h-index: 0
机构:
Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, SpainInst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain
机构:
Virginia Commonwealth Univ, Med Coll Virginia, Div Infect Dis, Richmond, VA 23219 USAVirginia Commonwealth Univ, Med Coll Virginia, Div Infect Dis, Richmond, VA 23219 USA